Human Metabolome Technologies chose Leiden for its European officeThursday, August 10, 2017
Hotspot for life sciences
Human Metabolome Technologies (HMT) has selected Leiden for three distinct reasons. First of all, the Netherlands has a strategic location in the centre of Europe which gives HMT a logistical advantage when receiving samples from clients in Europe, Africa and the Middle East. Additionally, the Leiden Bio Science Park which includes the Leiden University, the Leiden University Medical Centre and the dynamic cluster of pharmaceutical and biotech companies make up a great transitional research environment in which HMT can thrive.
Lastly but also important for the company and their Japanese culture, Leiden is the location where Philipp Franz von Siebold settled after leaving Japan. He was the first European physician to introduce Western medicine to Japan during the Sakoku era. This was an era of national isolation so the Japanese have a great admiration for Dr. Siebold and his work.
Tsutomu Hoshiba: “InnovationQuarter and NFIA have provided excellent support for the setup of our European office in beautiful and friendly Leiden. Their timely and pinpoint guidance made for an easy entry and now we are ready for business. Because of the InnovationQuarter staff diligence, our success is almost guaranteed.”
Human Metabolome Technologies (HMT) was founded in 2003 using a unique technology for metabolomic analysis. In 2013, HMT established their first overseas office in Boston, MA where they have expanded their business to around 100 projects in North America. HMT’s primary business aims to provide complete solutions for metabolome analysis in drug design, diagnostic technology, and food production, using a wide range of targets including human and animal samples. HMT is now ready to build on this success by opening this new office in the Netherlands so they can expand their reach and provide services to the European research community.
Established in Leiden
InnovationQuarter, the Leiden Bio Science Park foundation and the Netherlands Foreign Investment Agency (NFIA) offices in Boston, Japan and The Hague have provided information and assistance in setting up the office in Leiden and introductions in to the Life Science & Health business network in the region.
Mayor of Leiden Henri Lenferink: “We are pleased that HMT has chosen the Leiden Bio Science Park as the location for their European office. With their advanced metabolomic analysis technology, HMT will be a valuable addition to the Leiden life science cluster. And we are proud to have another strong tie to our long and warm relationship with Japan”.
“We are delighted with the establishment of HMT’s European office in our region,” says Chris van Voorden, Director Foreign Investments at InnovationQuarter. “Our team will continue to support HMT as they grow their European business and are excited to assist them in exploring possibilities for collaboration with regional partners and businesses.”
About Human Metabolome Technologies
Human Metabolome Technologies (HMT) is a global metabolomics contract research organization in operation since 2003 and solo provider of metabolomics based on CE-MS technology, which provides advantages in the quantitation of cellular metabolic intermediates compared with conventional technologies. HMT is an all-inclusive business model, working with clients from start to finish, including strategic, statistical and biological support.
The NFIA (Netherlands Foreign Investment Agency) is an operational unit of the ministry of Economic Affairs. The NFIA helps and advises foreign companies on the establishment, rolling out and/or expansion of their international activities in the Netherlands. The NFIA was established nearly 40 years ago, and has since then supported nearly 5,000 companies from more than 60 countries in the establishment or expansion of their international activities in the Netherlands.
Besides its headquarters in The Hague, the NFIA has its own offices in the United Kingdom, Turkey, North America, Asia, the Middle East, South Africa and Brazil. Additionally, the NFIA works together with Dutch embassies, consulates-general, and other organizations representing the Dutch government abroad, as well as with a broad network of domestic partners under the Invest in Holland label. More information: www.investinholland.com.
InnovationQuarter is the regional development agency for West Holland. InnovationQuarter finances innovative and fast-growing companies, assists international companies in establishing their businesses in West Holland, and facilitates (international) collaboration between innovative entrepreneurs, knowledge institutes and government. In this way, and in cooperation with the business community, InnovationQuarter supports the development of West Holland to become one of the most innovative regions in Europe.
The InnovationQuarter investment fund IQCapital - which currently consists of € 80 million committed capital - offers venture capital to young technology companies and SMEs with growth plans in the region to bring new innovations to market. Through the fund, InnovationQuarter can raise the regional economy to a higher level.
InnovationQuarter is an initiative of the Ministry of Economic Affairs, the Province of South Holland, the Cities of Rotterdam, The Hague, Leiden, Delft, Drechtsteden, Westland and Zoetermeer, Delft University of Technology (TU Delft), Leiden University, the Leiden University Medical Center and Erasmus Medical Centre and Foundation HEID (Holding Fund for Economic Investment The Hague).
Photo: Sandra de Wild (NFIA), Henri Lenferink (Mayor of Leiden), Mr. Ryuji Kanno (HMT), Mr. Tsutomu Hoshiba (HMT), Mr. Hiroshi Inomata (Ambassador of Japan), Lissa Culbertson Boxy (InnovationQuarter).
Photography: © Daniel Verkijk
RUCONEST® provided clinically meaningful relief of symptoms in children with hereditary angioedema
Pharming and HAEi International Patient Organization announce partnership with Inceptua Medicines Access for “HAEi Global Access Program”
ProQR’s drug candidate QRX-421 for Usher syndrome receives orphan drug designation from FDA and EMA